

Investigator	Abstract#	Description	Medium	Notes	Investigator's Site
Ian Flinn	abs25-4514	Fixed treatment duration subcutaneous mosunetuzumab monotherapy in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma: Interim results from the Phase II MorningSun study	Oral		Tennessee Oncology
Ian Flinn	abs25-4494	Fixed-duration subcutaneous (SC) mosunetuzumab, with maintenance therapy, in patients (pts) with previously untreated high-tumor burden follicular lymphoma (HTB FL): Longer follow-up and exploratory circulating tumor (ct)DNA analysis of the Phase II MorningSun study	Oral		Tennessee Oncology
Ian Flinn	abs25-2841	ZUMA-25 preliminary analysis: A Phase 2 study of brexucabtagene autoleucel (brexu-cel) in patients (Pts) with relapsed/refractory (R/R) burkitt lymphoma (BL), substudy C	Oral		Tennessee Oncology
Ian Flinn	abs25-7068	Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study	Oral		Tennessee Oncology
Ian Flinn	abs25-4459	Fixed-duration subcutaneous mosunetuzumab demonstrates sustained clinically meaningful outcomes in patients with previously untreated, low-tumor burden follicular lymphoma	Poster		Tennessee Oncology
Ian Flinn	abs25-9098	Safety and efficacy of MT-601 in relapsed or refractory (r/r) Hodgkin lymphoma	Poster		Tennessee Oncology
Ian Flinn	abs25-7483	Pirtobrutinib in post-cbtki CLL/SLL: Final update from the Phase 1/2 BRUIN study with more than 5 years follow-up	Poster		Tennessee Oncology
Ian Flinn	abs25-7205	Sustained efficacy of zanubrutinib (zanu) vs bendamustine + rituximab (BR) in treatment (tx)-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN SLL/CLL) and continued favorable survival in non-randomized patients (pts) with del(17p): 6-year follow-up in the phase 3 SEQUOIA study	Poster		Tennessee Oncology
Ian Flinn	abs25-4474	Prognostic value of combining beta-2-microglobulin and total metabolic tumor volume in patients with follicular lymphoma: A post-hoc analysis of the relevance trial	Poster		Tennessee Oncology
Ian Flinn	abs25-399	Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies: A long-term follow-up	Poster		Tennessee Oncology

Ian Flinn	abs25-7094	Zanubrutinib + venetoclax for treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), including patients with del(17p) and/or TP53 mutation and unmutated immunoglobulin heavy-chain variable status: 3-year results from SEQUOIA arm D	Poster		Tennessee Oncology
Ian Flinn	abs25-11870	MT-601 demonstrates favorable safety and durable responses in relapsed or refractory (r/r) non-Hodgkin lymphoma (NHL)	Poster		Tennessee Oncology
Ian Flinn	abs25-14466	Evolution of expert and healthcare professional treatment recommendations in the management of Mantle Cell Lymphoma	Poster		
Jesús Berdeja	abs25-7487	Low-dose oral decitabine and cedazuridine among patients with low-risk myelodysplastic syndromes	Oral		Tennessee Oncology
Jesús Berdeja	abs25-2077	Phase 1 study of ktx-1001, a first-in-class oral MMSET/NSD2 inhibitor, demonstrates clinical activity in relapsed/refractory multiple myeloma	Oral		Tennessee Oncology
Jesús Berdeja	abs25-4065	Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: A CIBMTR analysis	Oral		Tennessee Oncology
Jesús Berdeja	abs25-13565	Impact of short-form, case-based continuing medical education on community clinicians' knowledge and competence in optimizing bispecific antibody therapy for Relapsed/Refractory multiple myeloma	Poster		Tennessee Oncology
Jesús Berdeja	abs25-14403	Comprehensive characterization of multiple myeloma genomes from bone marrow or peripheral blood with a novel clinical assay enables identification of resistance mechanisms	Poster		Tennessee Oncology
Jesús Berdeja	abs25-11949	Talquetamab, a GPRC5D×CD3 bispecific antibody, in combination with pomalidomide in patients with Relapsed/Refractory multiple myeloma: Updated safety and efficacy results from the Phase 1b monumental-2 study	Poster		Tennessee Oncology
Jesús Berdeja	abs25-9114	Assessment of pharmacodynamic efficacy biomarkers from A phase 1, first-in-human study of arlocabtagene autoleucel (arlo-cel) in relapsed and refractory multiple myeloma (RRMM)	Poster	Presenting	Tennessee Oncology
William Donnellan	abs25-1541	Clinical characteristics and response in olutasidenib-treated Relapsed/Refractory mLDH1 Acute Myeloid Leukemia (AML) patients with stable disease following two treatment cycles	Poster		Tennessee Oncology

Jonathan Abbas	abs25-14421	A first-in-human study of stx-0712, a CCR2+ cytotoxicity targeting chimera (CyTAC™) in patients with chronic myelomonocytic leukemia (CMML) and Acute Myeloid Leukemia (AML)	Poster		Tennessee Oncology
Jonathan Abbas	abs25-4624	Preliminary experience from the ODYSSEY trial: Efficacy and safety of momelotinib in combination with luspatercept in patients with transfusion-dependent myelofibrosis	Poster		Tennessee Oncology
Michael Byrne	abs25-11968	Acute Myeloid Leukemia (AML) with TP53 alteration and outcomes after allogeneic hematopoietic stem cell transplantation: A CIBMTR registry study	Poster		Tennessee Oncology
Bertrand Anz	abs25-4494	Fixed-duration subcutaneous (SC) mosunetuzumab, with maintenance therapy, in patients (pts) with previously untreated high-tumor burden follicular lymphoma (HTB FL): Longer follow-up and exploratory circulating tumor (ct)DNA analysis of the Phase II MorningSun study	Oral		Tennessee Oncology
Richard Zuniga	abs25-4494	Fixed-duration subcutaneous (SC) mosunetuzumab, with maintenance therapy, in patients (pts) with previously untreated high-tumor burden follicular lymphoma (HTB FL): Longer follow-up and exploratory circulating tumor (ct)DNA analysis of the Phase II MorningSun study	Oral		New York Cancer & Blood Specialists
Eric Lee	abs25-7603	Outpatient administration of epcoritamab monotherapy for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): Results from EPCORE NHL-6 by race and ethnicity	Poster		Los Angeles Cancer Network